Subcutaneous Tocilizumab in Monotherapy or in Combination with DMARD in Patients with Moderate to Severe Active Rheumatoid Arthritis: Observational Study to Describe Real-World Drug Retention Rate at 12 Months, Interim Analysis - Université de Bretagne Occidentale Accéder directement au contenu
Poster De Conférence Année : 2018

Subcutaneous Tocilizumab in Monotherapy or in Combination with DMARD in Patients with Moderate to Severe Active Rheumatoid Arthritis: Observational Study to Describe Real-World Drug Retention Rate at 12 Months, Interim Analysis

Domaines

Sciences du Vivant [q-bio]

Geneviève Michel  : Connectez-vous pour contacter le contributeur

https://hal.univ-brest.fr/hal-01950797

Soumis le : mardi 11 décembre 2018-09:26:15

Dernière modification le : mercredi 17 janvier 2024-09:52:07

Fichier non déposé

Dates et versions

hal-01950797 , version 1 (11-12-2018)

Identifiants

  • HAL Id : hal-01950797 , version 1

Citer

P. Hilliquin, T Barnetche, G Baudens, R. Niarra, I Idier, et al.. Subcutaneous Tocilizumab in Monotherapy or in Combination with DMARD in Patients with Moderate to Severe Active Rheumatoid Arthritis: Observational Study to Describe Real-World Drug Retention Rate at 12 Months, Interim Analysis. ACR/ARHP Annual Meeting, Oct 2018, Chicago, France. 70 (suppl 10) (Abstract 573), Arthritis Rheumatology. ⟨hal-01950797⟩

Exporter

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

UNIV-BREST IMMUNO IBSAM
28 Consultations
0 Téléchargements

Partager

Gmail Facebook X LinkedIn More